272 related articles for article (PubMed ID: 19692322)
1. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.
Silberstein JL; Millard F; Mehrazin R; Kopp R; Bazzi W; DiBlasio CJ; Patterson AL; Downs TM; Yunus F; Kane CJ; Derweesh IH
BJU Int; 2010 Nov; 106(9):1270-6. PubMed ID: 20394613
[TBL] [Abstract][Full Text] [Related]
3. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
4. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery.
Gorin MA; Ekwenna O; Soloway MS; Ciancio G
Urology; 2012 Feb; 79(2):e11. PubMed ID: 21676439
[TBL] [Abstract][Full Text] [Related]
5. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.
Ueda K; Noguchi M; Suekane S; Moriya F; Nagayoshi R; Ejima K; Momozono K; Matsuoka K
Kurume Med J; 2011; 58(3):95-8. PubMed ID: 22531125
[TBL] [Abstract][Full Text] [Related]
7. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J
Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123
[TBL] [Abstract][Full Text] [Related]
9. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
[TBL] [Abstract][Full Text] [Related]
10. Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
Shaw GL; Hussain M; Nair R; Bycroft J; Beltran L; Green JS; Powles T; Peters JL
Urol Int; 2012; 89(1):83-8. PubMed ID: 22614181
[TBL] [Abstract][Full Text] [Related]
11. Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
Teo M; Downey FP; McDermott RS
Clin Genitourin Cancer; 2013 Jun; 11(2):198-200. PubMed ID: 23276590
[No Abstract] [Full Text] [Related]
12. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
Bex A; van der Veldt AA; Blank C; van den Eertwegh AJ; Boven E; Horenblas S; Haanen J
World J Urol; 2009 Aug; 27(4):533-9. PubMed ID: 19145434
[TBL] [Abstract][Full Text] [Related]
13. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
Dall'Oglio MF; Sousa-Canavez JM; Tanno FY; Tiseo BC; Crippa A; Dos Reis ST; Leite KR; Srougi M
Int Braz J Urol; 2011; 37(2):180-5; discussion 185-6. PubMed ID: 21557834
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
[TBL] [Abstract][Full Text] [Related]
15. Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
Park I; Park K; Park S; Ahn Y; Ahn JH; Choi HJ; Jeong IG; Song C; Hong JH; Kim CS; Ahn H; Lee JL
Clin Genitourin Cancer; 2013 Sep; 11(3):276-82. PubMed ID: 23332873
[TBL] [Abstract][Full Text] [Related]
16. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
17. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
18. Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma.
Vaz MA; Pachón V; Grande E; Ferreiro R; Carrato A
Anticancer Drugs; 2011 Sep; 22(8):817-21. PubMed ID: 21566523
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Biswas S; Kelly J; Eisen T
Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
[TBL] [Abstract][Full Text] [Related]
20. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.
Rini BI; Garcia J; Elson P; Wood L; Shah S; Stephenson A; Salem M; Gong M; Fergany A; Rabets J; Kaouk J; Krishnamurthi V; Klein E; Dreicer R; Campbell S
J Urol; 2012 May; 187(5):1548-54. PubMed ID: 22425095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
